About Collegium Pharmaceutical (NASDAQ:COLL)
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:COLL
- CUSIP: N/A
- Web: www.collegiumpharma.com
- Market Cap: $347.1 million
- Outstanding Shares: 29,566,000
- 50 Day Moving Avg: $10.88
- 200 Day Moving Avg: $10.88
- 52 Week Range: $9.27 - $18.50
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.24
- P/E Growth: 0.00
- Annual Revenue: $7.44 million
- Price / Sales: 46.65
- Book Value: $3.23 per share
- Price / Book: 3.63
- EBITDA: ($97,950,000.00)
- Net Margins: -1,319.39%
- Return on Equity: -93.73%
- Return on Assets: -74.81%
- Current Ratio: 4.22%
- Quick Ratio: 4.17%
- Average Volume: 572,400 shs.
- Beta: -0.11
- Short Ratio: 20.34
Frequently Asked Questions for Collegium Pharmaceutical (NASDAQ:COLL)
What is Collegium Pharmaceutical's stock symbol?
Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."
How were Collegium Pharmaceutical's earnings last quarter?
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) posted its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.09. The business had revenue of $3.56 million for the quarter, compared to analysts' expectations of $4.07 million. Collegium Pharmaceutical had a negative net margin of 1,319.39% and a negative return on equity of 93.73%. View Collegium Pharmaceutical's Earnings History.
When will Collegium Pharmaceutical make its next earnings announcement?
Where is Collegium Pharmaceutical's stock going? Where will Collegium Pharmaceutical's stock price be in 2017?
5 brokers have issued 1 year target prices for Collegium Pharmaceutical's stock. Their predictions range from $14.00 to $25.00. On average, they anticipate Collegium Pharmaceutical's share price to reach $20.00 in the next twelve months. View Analyst Ratings for Collegium Pharmaceutical.
Who are some of Collegium Pharmaceutical's key competitors?
Some companies that are related to Collegium Pharmaceutical include SciClone Pharmaceuticals (SCLN), AMAG Pharmaceuticals (AMAG), Corium International (CORI), Teligent (TLGT), Aceto Corporation (ACET), Tetraphase Pharmaceuticals (TTPH), Aquinox Pharmaceuticals (AQXP), Neos Therapeutics (NEOS), Allergy Therapeutics plc (AGY), Adamis Pharmaceuticals Corporation (ADMP), Marinus Pharmaceuticals (MRNS), BioDelivery Sciences International (BDSI), Female Health Company (The) (VERU), Aralez Pharmaceuticals (ARLZ), BioLife Solutions (BLFS), Diurnal Group PLC (DNL), Evoke Pharma (EVOK) and Histogenics Corporation (HSGX).
Who are Collegium Pharmaceutical's key executives?
Collegium Pharmaceutical's management team includes the folowing people:
- Michael Thomas Heffernan, Chairman of the Board, President, Chief Executive Officer
- Paul Brannelly CPA, Chief Financial Officer, Executive Vice President
- Joseph J. Ciaffoni, Chief Operating Officer, Executive Vice President
- Douglas R. Carlson, Vice President - Corporate Development
- Alison B Fleming, Vice President of Product Development
- Ernest A. Kopecky Ph.D., Vice President - Clinical Development and Head of Neuroscience
- Kevin OKeeffe, Vice President - Market Access and Trade
- Steven Passik Ph.D., Vice President - Scientific Affairs, Education and Policy
- Said Saim Ph.D., Vice President of Pharmaceutical Development
- John Weet Ph.D., Vice President - Regulatory Affairs and Quality Assurance
When did Collegium Pharmaceutical IPO?
(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.
How do I buy Collegium Pharmaceutical stock?
Shares of Collegium Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Collegium Pharmaceutical's stock price today?
MarketBeat Community Rating for Collegium Pharmaceutical (NASDAQ COLL)MarketBeat's community ratings are surveys of what our community members think about Collegium Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Collegium Pharmaceutical stock can currently be purchased for approximately $11.74.
Earnings History for Collegium Pharmaceutical (NASDAQ:COLL)Earnings History by Quarter for Collegium Pharmaceutical (NASDAQ COLL)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/9/2017||Q2 2017||($0.81)||($0.72)||$4.07 million||$3.56 million||View||Listen|
|5/10/2017||Q1 2017||($0.98)||($0.79)||$3.55 million||$2.17 million||View||N/A|
|3/9/2017||Q4 2016||($1.07)||($1.02)||$1.79 million||$1.30 million||View||Listen|
|11/10/2016||Q3 2016||($1.09)||($1.13)||$1.00 million||$0.41 million||View||Listen|
Earnings Estimates for Collegium Pharmaceutical (NASDAQ:COLL)
2017 EPS Consensus Estimate: ($3.22)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Collegium Pharmaceutical (NASDAQ:COLL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Collegium Pharmaceutical (NASDAQ:COLL)
Insider Ownership Percentage: 25.76%Insider Trades by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)
Institutional Ownership Percentage: 83.04%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/12/2017||Paul Brannelly||Insider||Buy||10,000||$9.18||$91,800.00|| |
|8/12/2016||John A Fallon||Director||Buy||2,375||$10.59||$25,151.25|| |
|5/12/2015||John Gordon Freund||Director||Buy||150,000||$12.00||$1,800,000.00|| |
|5/12/2015||Longitude Capital Partners, Ll||Major Shareholder||Buy||200,000||$12.00||$2,400,000.00|| |
Headline Trends for Collegium Pharmaceutical (NASDAQ:COLL)
Latest Headlines for Collegium Pharmaceutical (NASDAQ:COLL)
Loading headlines, please wait.
Collegium Pharmaceutical (COLL) Chart for Monday, October, 23, 2017